NGM·Healthcare·$1.1B·#241 / 520 in Healthcare
URGN UroGen Pharma Ltd.
47SPECULATIVE
CATEGORY BREAKDOWN
GROWTH34
QUALITY60
STABILITY47
VALUATION44
GOVERNANCE42
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+21.4%
34
> 50% strong
Gross Margin
Revenue retained after direct costs
88.7%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
8 months
21
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-121.7%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
10.4x
44
< 3x strong
Rule of 40
Growth rate plus operating margin
-92
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.7%
29
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+5.6%
66
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE URGN WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when URGN's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.